Division of Cardiovascular Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
Division of Cardiovascular Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
Ann Thorac Surg. 2019 Sep;108(3):e157-e159. doi: 10.1016/j.athoracsur.2019.01.065. Epub 2019 Mar 7.
Methotrexate has been reported as an immunosuppressive agent associated with lymphoproliferative disorders. This report describes the case of a cardiac methotrexate-induced lymphoproliferative disorder that could be differentiated from a sinus of Valsalva aneurysm rupture by cardiac magnetic resonance imaging and fluorine-18 (F)-fluorodeoxyglucose positron emission tomography combined with computed tomography. The definitive diagnosis was made by a tissue biopsy that was concomitantly performed with sinus of Valsalva aneurysm repair. Significant regression was seen in response to methotrexate withdrawal. To the best of our knowledge, this is the first case of a cardiac methotrexate-induced lymphoproliferative disorder.
甲氨蝶呤已被报道为一种与淋巴增生性疾病相关的免疫抑制剂。本报告描述了一例心脏甲氨蝶呤诱导的淋巴增生性疾病,通过心脏磁共振成像和氟-18(F)-氟脱氧葡萄糖正电子发射断层扫描结合计算机断层扫描可以与主动脉窦破裂相区别。通过与主动脉窦瘤修补术同时进行的组织活检做出了明确的诊断。停用甲氨蝶呤后观察到显著消退。据我们所知,这是首例心脏甲氨蝶呤诱导的淋巴增生性疾病。